Shares of Opko Health Inc. (NYSE:OPK) ended Monday session in green amid volatile trading. The shares closed up +0.05 points or 0.54% at $9.28 with 4.21 million shares getting traded. Post opening the session at $9.07, the shares hit an intraday low of $8.97 and an intraday high of $9.33 and the price vacillated in this range throughout the day. The company has a market cap of $5.18 billion and the numbers of outstanding shares have been calculated to be 547.44 million shares.
Opko Health Inc. (OPK) on May 11, 2016 announced the appointment of Douglass Laidlaw, PhD as Vice President of Medical Affairs to support the anticipated launch of RAYALDEE®.
Dr. Laidlaw has over 15 years of experience in leading strategic planning, development and execution of medical education initiatives for numerous pharmaceutical companies, including Relypsa, Keryx, Sanofi, Genzyme, Neurocine Biosciences, Serono and Organon. He has been involved in new product launches targeting patients with chronic kidney disease and has deep connections with key nephrology opinion leaders. Prior to joining OPKO, Dr. Laidlaw served as Relypsa’s Executive Director, Medical Affairs, and Sanofi’s National Director, Medical Science Liaisons, Medical Affairs.
“Doug is a key addition to the management team in OPKO’s Renal Division,” said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO. “A well-conceived and executed medical education strategy is critical to Rayaldee’s acceptance by U.S. healthcare professionals.”
Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) ended Monday session in red amid volatile trading. The shares closed down -1.49 points or -7.90% at $17.38 with 4.18 million shares getting traded. Post opening the session at $18.76, the shares hit an intraday low of $17.03 and an intraday high of $18.90 and the price vacillated in this range throughout the day. The company has a market cap of $823.79 million and the numbers of outstanding shares have been calculated to be 47.93 million shares.
Sarepta Therapeutics Inc (SRPT) on June 9, 2016 announced that Sarepta, through Credit Suisse and Robert W. Baird & Co., agreed to sell an amount of its common stock equal to approximately $37.5 million in gross proceeds in an underwritten offering, before deducting underwriting discounts and commission and other estimated offering expenses.
Credit Suisse and Robert W. Baird & Co. are acting as joint book-running managers of the offering. The underwriters may offer the shares of common stock from time to time to purchasers directly or through agents, or through brokers in brokerage transactions on the Nasdaq Global Select Market, or to dealers in negotiated transactions or in a combination of such methods of sale, at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices.